Jan 25, 2026
Most ViewedPurisaki Patch
markets transdermal patches and related wellness patches as a pill‑free way to curb appetite, support metabolism, and provide steady ingredient delivery through the skin, framing the product as a diet...
GLP-1 receptor agonists
Medications that mimic the gut hormone GLP-1, used for weight loss and glycemic control.
Fact-Checks
26 resultsJan 25, 2026
Most ViewedFatty liver reversal
(MASLD/NAFLD) is a highly prevalent, often “silent” condition in which excess fat accumulates in the liver and is closely linked to , and . Substantial clinical and observational evidence shows that e...
Jan 14, 2026
Most ViewedWhat peer‑reviewed research has Dr. Ania Jastreboff published on GLP‑1 medications and neural responses to food cues?
Dr. Ania M. Jastreboff has authored peer‑reviewed reviews and clinical trial publications that situate GLP‑1 receptor agonists within modern obesity therapeutics and has led high‑profile clinical tria...
Jan 17, 2026
What criteria do the ADA Standards of Care—2026 use to define and recommend diabetes remission strategies?
The 2026 ADA Standards of Care adopt a pragmatic, evidence-rooted definition of type 2 diabetes remission based on sustained normal glycemia off glucose‑lowering therapy and pair this definition with ...
Jan 13, 2026
What legitimate medical treatments currently approved for type 2 diabetes have evidence for remission, and how do they differ from ‘miracle cure’ ads?
There are legitimate, FDA‑approved treatments for type 2 diabetes that have evidence of producing remission—most strongly metabolic/bariatric surgery and intentional substantial weight loss through st...
Jan 13, 2026
How common is weight regain after stopping GLP‑1 weight‑loss medications, according to clinical studies?
Clinical trials and systematic reviews consistently find that weight regain after stopping GLP‑1 and other weight‑loss medications is common and often rapid: pooled analyses project return to baseline...
Jan 26, 2026
What clinical trials and safety data support Gelatide or similar commercially sold weight‑loss liquid drops?
Commercial products marketed as weight‑loss “liquid drops” like have little to no publicly available, peer‑reviewed clinical trial evidence demonstrating efficacy or a robust safety dataset, while man...
Jan 17, 2026
What barriers (cost, access, training) limit use of CGM and newer diabetes medications in underserved populations?
Continuous glucose monitors (CGMs) and newer glucose-lowering agents such as GLP‑1 receptor agonists and SGLT2 inhibitors promise better outcomes, but their uptake in underserved populations is constr...
Jan 31, 2026
Ozempic natural alternatives
(semaglutide) is a receptor agonist that suppresses appetite and alters glycemic physiology, and while no natural option perfectly replicates its potency or mechanism, multiple lifestyle strategies, f...
Jan 29, 2026
What are the clinical effects and side‑effects of Bydureon compared with other Type 2 diabetes treatments?
( extended‑release) is a once‑weekly GLP‑1 receptor agonist that reduces HbA1c and improves versus placebo and many oral agents, but its efficacy for weight loss and magnitude of glycemic lowering app...
Jan 25, 2026
How do prescription weight-loss drugs compare in safety to over-the-counter fat burners?
are generally backed by clinical trials, regulatory review, and medical monitoring and therefore carry clearer, better‑characterized safety profiles than most over‑the‑counter (OTC) “fat burners,” whi...
Jan 22, 2026
What peer‑reviewed clinical trials exist for Gelatide or its core ingredients?
No peer‑reviewed clinical trials of as a branded product have been identified in the provided reporting, and the manufacturer itself acknowledges an absence of published human trials for the product’s...
Jan 19, 2026
What are common side effects and safety tips for tirzepatide users?
Tirzepatide is a dual GIP/GLP‑1 receptor agonist approved for type 2 diabetes and chronic weight management that shows substantial efficacy but carries a predictable cluster of adverse effects—primari...
Jan 19, 2026
What peer-reviewed treatments and lifestyle changes have proven effectiveness for managing type 2 diabetes?
Intensive, evidence-based lifestyle interventions—centering nutrition, physical activity, sleep, stress management, social support, and avoidance of risky substances—consistently improve glycemic cont...
Jan 19, 2026
How do remission rates compare between intensive lifestyle programs, GLP‑1 receptor agonist therapy, and bariatric surgery in randomized trials?
Randomized-trial evidence shows that structured intensive lifestyle programs can induce remission of type 2 diabetes in a meaningful minority of participants, GLP‑1 receptor agonists produce larger sh...
Jan 18, 2026
How do GLP‑1 and GLP‑1/GIP receptor agonists compare to very low calorie diets in randomized trials measuring drug‑off remission?
Randomized trials show two contrasting pathways to diabetes remission and weight loss: intensive very low calorie diets (VLCDs) can produce drug‑off remission with lasting benefit in protocolized prog...
Jan 18, 2026
What do guidelines recommend for choosing GLP‑1 RA vs SGLT‑2 inhibitor in patients with type 2 diabetes and eGFR <45 mL/min/1.73 m2?
Guidelines converge on a risk‑based, not purely glycemia‑based, choice: SGLT2 inhibitors are recommended for cardiorenal protection down to low eGFR thresholds (often ≥20 mL/min/1.73 m2) despite reduc...
Jan 17, 2026
What are the documented drug interactions and safety signals for berberine, bitter melon, and other botanicals linked to GLP‑1?
Berberine is the best‑documented botanical tied to GLP‑1 biology: laboratory and animal studies show it can stimulate GLP‑1 secretion via bitter‑taste receptor and PLC‑dependent pathways and through a...
Jan 17, 2026
What are reputable, evidence‑based treatments and management strategies for type 2 diabetes?
Reputable, evidence-based management of type 2 diabetes blends lifestyle intervention, weight management (including bariatric surgery when appropriate), individualized pharmacotherapy, diabetes techno...
Jan 17, 2026
What strategies (tapering, combination drugs, or intensive behavioral programs) have been tested to prevent weight regain after stopping semaglutide?
Stopping semaglutide commonly triggers substantial weight regain: randomized trials and extensions show most people regain the majority of lost weight within a year to two years after drug withdrawal ...